Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Toxic antibodies blitz tumours

Nature (2011)Cite this article

Subjects

Tightly targeted cancer therapy receives marketing approval.

Eventually, Clay Siegall got used to doors slamming in his face. When the cancer researcher decided to create a company that would fight cancer using weaponized antibodies, investors were sceptical. "We contacted 35, then 40, then 45 venture-capital companies," he says. "We got turned down over and over and over."

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. DeCarvalho, S., Rand, H. J. & Lewis, A. Nature 202, 255-258 (1964).

    Article  ADS  CAS  Google Scholar 

  2. Junutula, J. R. et al. Nature Biotechnol. 26, 925-932 (2008).

    Article  CAS  Google Scholar 

Download references

Authors
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Cancer Genomics special

Translational Cancer Research special

Related external links

Seattle Genetics

ImmunoGen

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ledford, H. Toxic antibodies blitz tumours. Nature (2011). https://doi.org/10.1038/476380a

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/476380a

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing